The development and hosting of this resource hub has been sponsored by GSK. This resource hub contains links to clinical resources, some of which may be promotional in nature.
An introduction to IMPACT
Trelegy▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol 92/55/22 mcg) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA or a combination of a LAMA and a LABA.1
Relvar Ellipta (fluticasone furoate/vilanterol 92/22 mcg) is indicated for the symptomatic treatment of adults with COPD with a FEV₁ <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.2
Anoro▼ Ellipta (umeclidinium/vilanterol 55/22 mcg) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.3
- Trelegy Ellipta SmPC 2018.
- Relvar Ellipta SmPC 2018.
- Anoro Ellipta SmPC 2018.
IMPACT: the key facts and figures
Relvar Ellipta 184/22 mcg is not licensed in COPD
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
Trademarks are owned by or licensed to the GSK group of companies.
Date of preparation: February 2019.